17 stories mentioning BOM:524804Updated just now
Every FINWIRES story that references BOM:524804, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) said a US Food and Drug Administration inspection of its Unit-IV API manufacturing facility in Andhra Pradesh, India, concluded with zero observations.The inspection was conducted from Sept. 7 to Sept. 11 at the facility operated by wholly owned subsidiary Apitoria Pharma, according to an Indian bourse filing by the pharma company.
Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) said its step-down subsidiary A1 Biochem Labs (India) subscribed to 100% of A1 Biochem USA for $1 million, according to a Saturday exchange filing.A1 Biochem USA was incorporated on Aug. 27 and will provide contract research and development services as part of Aurobindo's acquisition of the A1 Biochem Group.The investment comprises 10,000 equity shares at $100 each and was completed on Sept. 11. The new subsidiary has yet to commence business.
Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) said its wholly owned subsidiary Apitoria Pharma has incorporated Avogent Lifesciences as a wholly owned subsidiary in India, according to a Tuesday bourse filing.The new entity will undertake manufacturing and marketing activities in India and overseas and has an initial share capital of 50 million Indian rupees.
Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) said a routine inspection of its wholly owned step-down subsidiary, Lannett Co. in Seymour, Indiana, by U.S. Food and Drug Administration, concluded with four observations.The inspection was conducted from Aug. 17 to 21, according to a Monday filing on NSE. The company said the observations were procedural in nature and it will respond to the U.S. FDA within the specified timeline.
Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) approved a proposal to merge step-down subsidiaries Eugia Steriles and Eugia SEZ into wholly owned subsidiary Eugia Pharma Specialties, according to a Wednesday exchange filing.The merger, which is subject to approval by the National Company Law Tribunal in Hyderabad, aims to simplify the group's corporate structure.The company said the amalgamation is expected to reduce corporate and administrative costs, improve treasury management, and generate operational synergies.No consideration will be paid as the transaction involves wholly owned subsidiaries, and Aurobindo Pharma's shareholding pattern will remain unchanged.
Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) said its wholly owned step-down subsidiary, PT Aurogen Pharma Indonesia, has incorporated PT Auro Pharm Indonesia as a wholly owned subsidiary in Indonesia.The new company will undertake manufacturing operations in Indonesia and has an initial subscribed share capital of 20 billion Indonesian rupiah, according to a stock exchange filing.
Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) has acquired a 26% equity stake in Swarnaakshu Solar Power through an initial investment of 5.2 million Indian rupees.The pharma company also signed a power purchase agreement to procure solar power for captive consumption, according to a Thursday stock exchange filing.The company had earlier approved an investment of up to 104 million rupees in Swarnaakshu. The remaining investment will be made in phases depending on project progress and funding needs.Shares of the company rose nearly 2% in morning trade on Friday.
Aurobindo Pharma's (NSE:AUROPHARMA, BOM:524804) wholly owned U.S.-based subsidiary has received approval from the U.S. Federal Trade Commission for the $250-million deal to acquire Lannett Company, according to a Monay filing to the Indian stock exchanges.The transaction is expected to close before the end of June.US-based Lannett specializes in the development and commercialization of complex, non-opioid controlled substances. Its acquisition is expected to expand Aurobindo USA's product offering.It will also add Lannett's manufacturing facility in the U.S. to its network. The unit has the capacity to scale production to around 4 billion doses annually.The acquisition is expected to be immediately accretive to Aurobindo Group's earnings per share and offer near-term financial benefits, along with cost and operational efficiencies.
Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) on Wednesday inaugurated a biologics contract manufacturing facility of its subsidiary Theranym Biologics at Borapatla in Telangana, India, according to a same-day filing to the Indian stock exchanges.This marks Aurobindo's foray into biologics contract manufacturing.The company has roped in pharmaceutical company MSD as an anchor customer for the facility and will help to support the latter's supply chain in both domestic and export markets.
Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) reported a slight increase in its consolidated attributable net profit to 9.21 billion Indian rupees in the fiscal fourth quarter ended March 31, against 9.03 billion rupees a year ago.Shares of the company fell over 6% in Friday's trade.Earnings per share inched up to 15.86 rupees compared with the year-ago figure of 15.56 rupees, according to a Thursday filing to the Indian stock exchanges by the pharmaceutical manufacturer.Revenue from operations in fiscal Q4 increased to 87.5 billion rupees from 83.8 billion rupees a year earlier.
Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) has received a "voluntary action indicated" from the US Food and Drug Administration (US FDA) after the inspection of its oral solid dosage manufacturing unit in the Mahaboobnagar district of Telangana, India.The inspection, which was conducted between Jan. 28 and Feb. 10, resulted in the US FDA issuing a 'Form 483' with nine observations, according to a Wednesday filing to the Indian stock exchanges.With this classification, the inspection is now closed.The company's shares were up over 3% in recent trade.
Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) said Sanjay Chaturvedi has resigned as chief executive officer of the company's wholly owned subsidiary, Apitoria Pharma, effective May 4.Chaturvedi has stepped down to pursue another opportunity, according to a Monday filing on Indian bourses.Shares of Aurobindo Pharma rose over 3% in Tuesday's trade.
Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) said its chief business officer for emerging markets N. Ravi Kiran will retire from the company, effective April 30, according to a same-day filing on Indian bourses.
Indian benchmark indices ended higher on Friday as broad-based buying lifted markets, supported by gains in consumer goods and oil & gas stocks.The BSE Sensex rose 504.86 points, or 0.7%, to close at 78,493.54, while the NSE Nifty 50 gained 156.80 points, or also 0.7%, to settle at 24,353.55.Sentiment improved on expectations of easing tensions in the Middle East. Reports of a possible progress in U.S.-Iran negotiations and a potential extension of the ceasefire supported risk appetite.A sharp decline in crude oil prices further supported the market.In corporate developments, Bajaj Consumer Care (NSE:BAJAJCON, BOM:533229) reported a rise in consolidated profit to 636.0 million rupees in the fiscal fourth quarter from 309.8 million rupees a year earlier.Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) received U.S. FDA approval to manufacture and market Glycerol Phenylbutyrate Oral Liquid. The product is equivalent to the reference drug Ravicti and will be launched immediately, the company said in a Friday filing.
Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) has received final approval from the US Food and Drug Administration (US FDA) to manufacture and market Glycerol Phenylbutyrate Oral Liquid, according to a Friday filing to the Indian stock exchanges.The drug is bioequivalent and therapeutically equivalent to Horizon Therapeutics' reference-listed drug Ravicti Oral Liquid. It will be manufactured in the company's third unit and will be launched immediately.Glycerol Phenylbutyrate is used as a nitrogen-binding agent for chronic management of patients with urea cycle disorders.According to IQVIA's estimates, Horizon has an estimated market size of $50.2 million for the 12 months ended February.
